In this issue:
Efficacy and safety of dupilumab versus placebo
Role of contact urticaria testing
Long-term outcomes of omalizumab
Safety profile of remibrutinib
Reasons for omalizumab discontinuation
Anti-TPO-negative versus anti-TPO-positive patients and their responses to omalizumab
Clinical and laboratory characteristics of HTR-CSU
Current insights for chronic inducible urticarias
Discussion about the current endotype-based model of CSU
Clinical evaluation and outcome measures for CSU
Please login below to download this issue (PDF)